🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Pfizer Limited PFIZER NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.pfizerltd.co.in

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

READ MORE ›
₹4,598.50
-15.28% 1Y

Market & Price

Market Cap
₹21,037.10 Cr
Current Price
₹4,598.50
High / Low (52W)
₹5,766.50 / ₹4,551.00
Beta
0.13

Valuation

Stock P/E
29.15
Industry PE
37.60
Forward P/E
22.65
PEG Ratio
-
Book Value
₹841.24
Price to Book
5.47
P/S
8.35
EV/EBITDA
19.91
Dividend Yield
1.63%

Profitability & Returns

ROCE
22.94%
ROE
17.16%
ROA
10.76%
Profit Margin
28.67%
Op Margin
35.15%
EPS (Latest Qtr)
₹43.68
EPS (TTM)
₹157.73

Balance Sheet & Liquidity

Debt/Equity
1.67
Quick Ratio
5.25
Current Ratio
6.06
Debt
₹70.23 Cr
Total Assets
₹4,921.88 Cr
Current Assets
₹3,803.19 Cr
Working Capital
₹3,175.71 Cr

Ownership

Promoter Holding
66.97%
Chg in Prom Hold
-
FII / Inst Holding
17.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹17,995.92 Cr
Total Revenue (TTM)
₹2,519.65 Cr
EBITDA
₹904.09 Cr
Free Cash Flow
₹671.97 Cr
Operating Cash Flow
₹967.57 Cr
Shares Outstanding
₹4.57 Cr
Gross Margin
64.90%
Payout Ratio
22.16%

Growth (CAGR)

Revenue 5Y
1.32%
Profit 5Y
5.01%
Revenue (YoY)
6.30%
Earnings (YoY)
-39.60%

PROS

  • Healthy ROCE of 22.9%.
  • Excellent profit margin of 28.7%.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PFIZER Pfizer Limited NIFTY_SMALLNSEPHARMA 4,598.50 29.15 ₹21,037.10 Cr 1.63% 22.94% 17.16% 1.32% 5.01%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 591.91 Cr603.05 Cr642.34 Cr645.03 Cr629.23 Cr
Cost of Revenue 202.48 Cr211.23 Cr227.95 Cr224.77 Cr220.36 Cr
Gross Profit 389.43 Cr391.82 Cr414.39 Cr420.26 Cr408.87 Cr
Operating Expenses 178.33 Cr196.21 Cr198.74 Cr206.33 Cr187.70 Cr
Operating Income 211.10 Cr195.61 Cr215.65 Cr213.93 Cr221.17 Cr
EBITDA 444.89 Cr277.19 Cr271.78 Cr208.20 Cr285.71 Cr
Interest Expense 2.69 Cr3.25 Cr2.13 Cr1.99 Cr2.11 Cr
Pretax Income 425.80 Cr259.53 Cr255.37 Cr191.95 Cr268.82 Cr
Tax Provision 94.86 Cr67.78 Cr66.35 Cr50.11 Cr69.00 Cr
Net Income 330.94 Cr191.75 Cr189.02 Cr141.84 Cr199.82 Cr
Diluted EPS 72.3441.9141.3231.0143.68

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -2,422.32 Cr2,192.69 Cr2,281.35 Cr2,519.65 Cr
Cost of Revenue -875.65 Cr795.23 Cr810.45 Cr884.31 Cr
Gross Profit -1,546.67 Cr1,397.46 Cr1,470.90 Cr1,635.34 Cr
Operating Expenses -837.89 Cr820.40 Cr791.46 Cr788.98 Cr
Operating Income -708.78 Cr577.06 Cr679.44 Cr846.36 Cr
EBITDA -942.91 Cr823.76 Cr1,085.29 Cr1,042.88 Cr
Interest Expense -13.39 Cr15.41 Cr8.41 Cr9.48 Cr
Pretax Income -824.01 Cr746.07 Cr1,016.09 Cr975.67 Cr
Tax Provision -200.08 Cr194.74 Cr248.49 Cr253.24 Cr
Net Income -623.93 Cr551.33 Cr767.60 Cr722.43 Cr
Diluted EPS 133.89136.38120.51167.79-

Compounded Sales Growth

5 Years:1.32%
1 Year:6.30%

Compounded Profit Growth

5 Years:5.01%
1 Year:-39.60%

Stock Price Performance

1 Year:-15.28%
6 Months:-7.45%
3 Months:-9.33%
1 Month:-3.45%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -4,000.73 Cr4,228.78 Cr4,911.11 Cr4,921.88 Cr
Current Assets -2,525.09 Cr2,769.56 Cr3,512.85 Cr3,803.19 Cr
Cash & Equivalents -36.60 Cr112.00 Cr495.07 Cr102.66 Cr
Inventory -417.70 Cr433.69 Cr475.92 Cr472.66 Cr
Receivables -151.73 Cr187.61 Cr193.09 Cr181.80 Cr
Total Liabilities -793.43 Cr633.24 Cr693.70 Cr718.98 Cr
Current Liabilities -657.35 Cr546.56 Cr569.51 Cr627.48 Cr
Long Term Debt -----
Total Debt -134.47 Cr94.54 Cr108.40 Cr70.23 Cr
Total Equity -3,207.30 Cr3,595.54 Cr4,217.41 Cr4,202.90 Cr
Shares Outstanding -4.57 Cr4.57 Cr4.57 Cr4.57 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -355.68 Cr256.84 Cr659.75 Cr967.57 Cr
Investing Cash Flow --36.05 Cr53.70 Cr-71.34 Cr-561.67 Cr
Financing Cash Flow --345.79 Cr-235.14 Cr-205.34 Cr-798.31 Cr
Capital Expenditure --64.98 Cr-18.93 Cr-28.15 Cr-25.23 Cr
Free Cash Flow -290.70 Cr237.91 Cr631.60 Cr942.34 Cr
Net Change in Cash --26.16 Cr75.40 Cr383.07 Cr-392.41 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -63.9%63.7%64.5%64.9%
Operating Margin % -29.3%26.3%29.8%33.6%
Net Margin % -25.8%25.1%33.6%28.7%
ROE % -19.5%15.3%18.2%17.2%
ROCE % -21.2%15.7%15.6%19.7%

Shareholding Pattern

Insiders
66.97%
Institutions
17.00%
Public Float
51.47%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PFIZER

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space